123 related articles for article (PubMed ID: 32670103)
41. THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial.
Vaccarino AL; Kalali AH; Blier P; Gilbert Evans S; Engelhardt N; Foster JA; Frey BN; Greist JH; Kobak KA; Lam RW; MacQueen G; Milev R; Müller DJ; Parikh SV; Placenza FM; Rizvi SJ; Rotzinger S; Sheehan DV; Sills T; Soares CN; Turecki G; Uher R; Williams JBW; Kennedy SH; Evans KR
Innov Clin Neurosci; 2020 Jul; 17(7-9):30-40. PubMed ID: 33520402
[No Abstract] [Full Text] [Related]
42. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
Krystal AD; Mittoux A; Meisels P; Baker RA
Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
[TBL] [Abstract][Full Text] [Related]
43. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity.
Cha DS; Carmona N; Cha RH; Zhou AJ; Subramaniapillai M; Mansur RB; Lee Y; Lee JH; Lee J; Almatham F; Alageel A; Rosenblat JD; Shekotikhina M; Rong C; Harrison J; McIntyre RS
Ann Clin Psychiatry; 2019 Feb; 31(1):17-26. PubMed ID: 30372511
[TBL] [Abstract][Full Text] [Related]
44. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
[TBL] [Abstract][Full Text] [Related]
45. Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder.
Kato M; Kikuchi T; Watanabe K; Sumiyoshi T; Moriguchi Y; Oudin Åström D; Christensen MC
Neuropsychiatr Dis Treat; 2024; 20():49-60. PubMed ID: 38239870
[TBL] [Abstract][Full Text] [Related]
46. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder.
Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
Prim Care Companion J Clin Psychiatry; 2009; 11(1):8-15. PubMed ID: 19333404
[TBL] [Abstract][Full Text] [Related]
47. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
48. Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J.
Sumiyoshi T; Watanabe K; Noto S; Sakamoto S; Moriguchi Y; Hammer-Helmich L; Fernandez J
Neuropsychiatr Dis Treat; 2021; 17():945-955. PubMed ID: 33814911
[TBL] [Abstract][Full Text] [Related]
49. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
50. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
51. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.
Harvey PD; Jacobson W; Zhong W; Nomikos GG; Cronquist Christensen M; Kurre Olsen C; Merikle E
J Affect Disord; 2017 Apr; 213():105-111. PubMed ID: 28213121
[TBL] [Abstract][Full Text] [Related]
52. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
McIntyre RS; Lee Y
Curr Opin Psychiatry; 2016 Jan; 29(1):48-55. PubMed ID: 26575300
[TBL] [Abstract][Full Text] [Related]
53. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
54. Associations between increased circulating endothelial progenitor cell levels and anxiety/depressive severity, cognitive deficit and function disability among patients with major depressive disorder.
Liou YJ; Chen MH; Hsu JW; Huang KL; Huang PH; Bai YM
Sci Rep; 2021 Sep; 11(1):18221. PubMed ID: 34521977
[TBL] [Abstract][Full Text] [Related]
55. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
56. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
58. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
59. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
[No Abstract] [Full Text] [Related]
60. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
